NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
Clinical Trials
18 trialsNCT01198067 2025-09-04
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT04843579 2023-10-25
ClaSPd
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02576977 2021-10-08
KEYNOTE 183
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT01946152 2021-07-30
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01999335 2021-04-27
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT03440411 2021-03-10
PO-3887
Fondazione EMN Italy Onlus
Phase 3 Terminated
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02548962 2019-11-21
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Pharmacyclics LLC.
Phase 1/2 Terminated
NCT00537511 2019-11-19
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
Celgene
Phase 1/2 Terminated
NCT00717522 2019-11-19
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
Celgene
Phase 2 Terminated
NCT02289222 2019-11-05
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01078974 2016-07-25
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01889420 2015-07-31
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
New Mexico Cancer Research Alliance
Phase 1 Terminated